Sprint Bioscience (Q3 review): Gilead deal a strong confirmation - Redeye

Redeye returns with an update on Sprint Bioscience following recent events and the Q3 report. We are impressed the recent progress that includes selling the TREX1 program to Gilead Sciences. With a robust cash position, the company should have more breathing room to continue with its internal programs and business development. We raise our base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1140555/sprint-bioscience-q3-review-gilead-deal-a-strong-confirmation?utm_source=finwire&utm_medium=RSS